Estimated | Norethindrone | Control Group (OCP) | p |
---|---|---|---|
N | 23 | 23 | |
Age | 27.7 (18–33) (0.883) | 28.0 (18–33) (.916) | 0.865 |
Race | White (26%), Hispanic (26%) | White (30%), Hispanic (18%) | ns |
African-American (22%), | African-American (30%), | ||
Asian (9%), Indian (13%) | Asian (13%), Indian (9%) | ||
Other (4%) | |||
Nulligravid | 11 | 12 | 0.768 |
Weight | 147.1 (96–221) (6.733) | 149.3 (100–235) (7.75) | 0.987 |
Cycle day start | 8.8 (2–14a) (0.613) | 8.2 (3–12) (0.603) | 0.514 |
Time to event | 29.7 (21–42) (1.405) | 30.61 (22–40) (1.283) | 0.650 |
Days on therapy | 33.4 (28–45) (1.152) | 33.2 (23–43) (1.177) | 0.916 |
Patients missing > 2 doses | 0 | 1 | 0.312 |
Patients with breakthrough bleed | 2a | 10 | 0.007 |
Average day bleed occurred | 16.5 (14–19) | 15.25 (10–23) (1.47) | NA |
Amount breakthrough bleeding | 1 | 1.5 (1–3) (0.726) | 0.321 |
Mean weight gain on therapy Of those, > 5 lbs. persistence at 1wk | 3.6 (0–7) (0.469) | 2.2 (0–6) (0.435) | 0.023 |
0 | 0 | ||
Patients with side effects | 5 | 12 | 0.054 |
Side effects | bloating (3), spotting (2) | bloating (2), spotting (9) | |
weight gain (4), nausea (1) | heavier bleeding (1), nausea (3) | ||
headache (1) | headache (2), sore breasts (2) | ||
Days stop therapy to menses | 3 (2–4) (0.167) | 3.17 (2–4) (0.136) | 0.537 |
Patients reporting light/normal flow | 13 | 20 | 0.047 |
Reported duration of flow as normal or shorter | 15 | 14 | 0.395 |
Satisfaction Score | 4.09 (3–5) (0.153) | 3.56 (2–5) (0.176) | 0.041 |
Likely to use method again | 4.13 (3–5) (0.158) | 3.522 (2–5) (0.165) | 0.013 |
Likely to recommend method | 4.17 (3–5) (0.162) | 3.39 (2–5) (0.137) | 0.002 |
Unintended pregnancies | 0 | 0 | |
Desire to conceive in 1 year | 4 | 5 | 0.710 |
Time to conceive (months) | 2.0 (1–3) (0.170) | 3.6 (3–5) (0.186) | 0.032 |